treatment was first relapse after conventional chemotherapy in seven, first relapse after autologous stem cell transplantation in 16, stable disease after conventional chemotherapy in five, stable disease after autologous stem cell transplantation in four, and previously untreated MM in three patients. The median number of lines of therapy before clarithromycin treatment was two (0-3). Response was evaluated using the Myeloma Task Force criteria of 50% reduction in M-band concentration.
treatment was first relapse after conventional chemotherapy in seven, first relapse after autologous stem cell transplantation in 16, stable disease after conventional chemotherapy in five, stable disease after autologous stem cell transplantation in four, and previously untreated MM in three patients. The median number of lines of therapy before clarithromycin treatment was two (0-3). Response was evaluated using the Myeloma Task Force criteria of 50% reduction in M-band concentration. 3 From December 1997 to April 1998, patients received a continuous course of 500 to 1000 mg clarithromycin (median dose 500 mg twice a day), and neither chemotherapy nor steroids were added during antibiotic treatment. Clarithromycin was well tolerated in 69% of cases, but 31% of patients (11/35 patients) experienced gastric pain, anorexia, nausea or diarrhea. After a median time of 8 weeks (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , no patient responded to clarithromycin therapy, and MM progressed in 80% of cases, requiring other therapeutic approaches.
We conclude that clarithromycin antibiotic treatment has no efficacy in patients with MM. The difference observed between our data and the results of Durie et al might be due to the addition of steroids to clarithromycin treatment.
Trisomy 8 as a secondary genetic change in acute megakaryoblastic leukemia associated with Down's syndrome TO 
THE EDITOR
Children with Down's syndrome (DS) have an approximately 10-20-fold increased incidence of acute leukemia. 1 There is an increased incidence of both acute lymphoblastic leukemia and acute myeloid leukemia (AML), in particular acute megakaryoblastic leukemia (AMKL). Neonates with DS are also at risk of developing a syndrome mimicking acute leukemia that resolves spontaneously, termed transient abnormal myelopoiesis (TAM), in which blast cells show evidence of megakaryoblastic differentiation. 2 We present a case of AMKL associated with DS which showed a clonal karyotypic abnormality of trisomy 8(+8) in addition to constitutional trisomy 21 (+21). Fluorescence in situ hybridization (FISH) with a centromeric chromosome 8 probe on bone marrow cells was performed in an attempt to delineate lineage involvement in AMKL associated with DS.
A 19-month-old baby girl with DS presented with easy bruising. There was no known history of TAM in the neonatal period. Physical examination showed no organomegaly or lymphadenopathy. The complete blood counts showed: hemoglobin 9.9 g/dl, white cell count 5.2 × 10 9 /l (blasts 12%), and platelet count 22 × 10 9 /l. A bone marrow aspirate showed increased blasts (25%) with undifferentiated morphology. Megakaryocytes were reduced, but both erythropoiesis and granulopoiesis were preserved. No definite myelodysplastic feature was observed. The blast cells were cytochemically inert but surface marker analysis revealed positivity for platelet-associated antigens CD41 and CD42b in addition to CD33 (myeloid marker), glycophorin-A (erythroid marker) and CD7 (T cell marker which is also aberrantly expressed in AML). A diagnosis of AMKL associated with DS was made. Cytogenetic study on bone marrow cells showed the following karyotype: 48,XX,+8,+21 [2] /47,XX,+21 [10] . Molecular analysis by reverse-transcription polymerase chain reaction showed positivity for Wilm's tumour gene (wt1) transcript, which has recently been shown to occur in the majority of human acute leukemias. 3 The patient was treated with the United Kingdom AML XII protocol with mitozantrone. Unfortunately she died of fulminant pneumonia during induction chemotherapy.
FISH was performed on bone marrow cells using a directly labeled chromosome 8 centromeric probe (Vysis, Downers Grove, IL, USA) according to protocol of the manufacturer. The image was captured and analyzed by a Leica Q550CW Cytogenetics Workstation (Leica Imaging System, Cambridge, UK), and signals were analyzed in 300 cells. The slide was then stained with Wright-Giemsa and cells were relocated for morphological correlation with FISH signals. Trisomy 8 was confined to the blast population and was not detected in myeloid cells, erythroblasts and lymphocytes that were analyzed (Figure 1) . Out of 75 blast cells analyzed, 45 (61%) showed three hybridization signals and thus harbored +8 (Figure 1 ). The false positive and negative rate on a control slide run in parallel were 0% and 2%, respectively. While +8 has previously been recognized as a clonal karyotypic abnormality in acute leukemia associated with DS, 2 its role in leukemogenesis remains to be defined. In our patient with DS and AMKL, +8 was present in a subpopulation of blasts only and therefore represents a secondary genetic change in leukemogenesis. The absence of +8 in other lineages does not necessarily imply their being normal, since the primary event is not known. In fact, current data from cell culture experiments, blast cell phenotype and gene rearrangement studies support involvement of an early hemopoietic cell capable of multilineage differentiation in AMKL associated with DS. 1 In TAM associated with DS, the abnormal proliferation of blast cells is linked to the presence of an extra copy of chromosome 21. Support for this contention is provided by cases of TAM in a phenotypically normal newborn with +21 mosaicism 4 and in two genetically normal neonates, 5 in whom the abnormal proliferating population also harbors +21. Although the clinical course of TAM is that of spontaneous resolution, around 25% of such patients will relapse as AMKL later on in life, usually within 3 years. 1 Conversely, DS with AMKL will, with rare exceptions including our case, give a history of TAM in the neonatal period. 6 Taken together, these observations suggest that accumulation of genetic events in addition to +21 may be responsible for subsequent relapse of TAM. The fact that karyotypic abnormalities 7 besides +21 are much more frequently encountered in AMKL than in TAM are consistent with this hypothesis. The present study shows that one such cytogenetic change, namely +8, occurs only as a secondary/evolutionary event in the leukemogenic process and that important primary genetic events related to development of AMKL in DS remains to be established. 
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